Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, CRISPR Therapeutics (CRSP) has a market cap of $3.34 billion USD. According to our data, CRISPR Therapeutics is ranked No.3192 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $3.34 B |
-1.04%
|
| Dec 31, 2024 | $3.38 B |
-37.12%
|
| Dec 29, 2023 | $5.37 B |
54.00%
|
| Dec 30, 2022 | $3.49 B |
-46.36%
|
| Dec 31, 2021 | $6.50 B |
-50.51%
|
| Dec 31, 2020 | $13.13 B |
151.39%
|
| Dec 31, 2019 | $5.22 B |
113.18%
|
| Dec 31, 2018 | $2.45 B |
21.68%
|
| Dec 29, 2017 | $2.01 B |
15.89%
|
| Dec 30, 2016 | $1.74 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Editas Medicine
EDIT
|
$0.11 B |
0.000 M
|
USA
|
 Intellia Therapeutics
NTLA
|
$0.76 B |
-0.000 M
|
USA
|
 Beam Therapeutics
BEAM
|
$1.73 B |
0.000 M
|
USA
|
 Sangamo Therapeutics
SGMO
|
$0.17 B |
0.000 M
|
USA
|
 bluebird bio
BLUE
|
$43.76 M |
0.000 M
|
USA
|
 REGENXBIO
RGNX
|
$0.33 B |
-0.000 M
|
USA
|
 CRISPR Therapeutics
CRSP
|
$3.34 B |
0.000 M
|
Switzerland
|
 Vertex Pharmaceuticals
VRTX
|
$128.67 B |
-0.003 M
|
USA
|
 Moderna
MRNA
|
$10.14 B |
-0.001 M
|
USA
|
 BioNTech
BNTX
|
$23.80 B |
0.001 M
|
Germany
|
 Pfizer
PFE
|
$127.27 B |
-0.003 M
|
USA
|
 Novartis
NVS
|
$217.12 B |
0.003 M
|
Switzerland
|
 Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
USA
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
| Market Cap | = | CRSP Stock Price | * | CRSP Shares Outstanding |
| = | $38.95 | * | 85.77 M | |
| = | $3.34 B |